5-Bromo-4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine, 95.0%, 1g

TASQUINIMOD, 95%, 100mg

2-Isocyanosuccinic acid dimethyl ester, 1g

3-(2,4-Dichlorophenyl)-1-ethyl-1H-pyrazole-5-carboxylic acid, 95.0%, 1g

(R)-1-(3-Chloro-4-methylphenyl)ethanamine hydrochloride, 95.0%, 5g

N-isobutyl-3-nitro-2-pyridinamine, 95.0%, 1g

1-Methyl-5-phenoxy-3-(trifluoromethyl)-1H-pyrazole-4-carbaldehyde, 95.0%, 250mg

N,N-dietilanilina, >=98,5%, per sintesi, 250 ml, confezione in vetro

(E)-2-(2-(cyclohex-1-en-1-yl)vinyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 250mg

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, 99.0%, 1g

Benzyl 3-(2-ethoxy-2-oxo-ethylidene)azetidine-1-carboxylate, 98%, 5g

(S)-2-Amino-3-(2,4-dichlorophenyl)propanoic acid, 95.0%, 5g

tert-Butyl 3-fluoro-4,4-dihydroxypiperidine-1-carboxylate, 95%, 250g